In addition to de novo HER2 AMP, an acquired resistance mechanism has been identified in advanced oncogene addicted-NSCLC treated with TKIs, occurring, for example, in approximately 7–15% of cases after post-treatment with EGFR-TKI [47]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.